Introduction How Can We Help? Deliverables Key Benefits Related Products FAQs Contact
Are you currently facing challenges in solid tumor penetration, systemic toxicity, and drug resistance associated with traditional biotherapeutics? Our Aptamer-Drug Conjugates (ApDCs) Development Service helps you design and construct highly specific, scalable, and non-immunogenic cancer therapeutics through proprietary Cell-SELEX aptamer screening and advanced bioconjugation chemistry, overcoming the limitations of conventional ADCs.
Introduction of ApDCs Development for Targeted and Precision Cancer Therapy
What Is Our Service?
Our ApDCs Development Service is a comprehensive platform that handles the entire pipeline, from novel aptamer discovery to the final conjugation of the cytotoxic payload. ApDCs are composed of three critical elements: a high-affinity aptamer, a stable linker, and a potent cytotoxic drug (payload). The aptamer selectively binds to an overexpressed tumor-specific marker and facilitates receptor-mediated endocytosis, effectively delivering the drug cargo into the cancer cell's lysosomal compartment for localized release. Application Scenarios:
-
Solid Tumor Therapy: Designing small-sized ApDCs to overcome the poor tissue penetration barriers inherent in dense solid tumors.
-
Overcoming Drug Resistance: Employing aptamers that target surface markers associated with multi-drug resistance mechanisms, delivering drugs past efflux pumps.
-
Theranostic Applications: Developing aptamers conjugated with both a therapeutic agent and a diagnostic imaging label for simultaneous treatment and real-time monitoring of tumor response.
Why Choose Us?
Creative Biolabs provides unparalleled value by directly addressing the core limitations of developing first-generation targeted therapies.
|
Pain Points
|
Benefit Created by Creative Biolabs
|
|
Poor Tumor Penetration
|
Small Molecular Size: Aptamers are significantly smaller, ensuring superior diffusion and deep penetration into the tumor microenvironment.
|
|
High Immunogenicity & Cost
|
Non-Immunogenic & Scalable: Aptamers are chemically synthesized, resulting in lower cost of goods (COGS), high purity, and virtually zero immunogenicity in patients.
|
|
Systemic Off-Target Toxicity
|
Tunable Half-Life & Cleavable Linkers: We engineer linkers that only release the payload in the low-pH or high-enzyme environment of the lysosome, maximizing safety and minimizing systemic side effects.
|
Fig.1 Diagram depicting ApDC construction and its mechanism against pancreatic tumors.1
How Creative Biolabs' ApDCs Development Can Assist Your Project?
Creative Biolabs' service provides a turnkey solution for researchers and pharmaceutical companies seeking to leverage the power of aptamers for precision oncology. We ensure that every conjugate is optimized for stability, targeting affinity, and predictable release kinetics.
Workflow of ApDC Development
-
Required Starting Materials
-
Tumor Target Marker
-
Cytotoxic Payload
-
Existing Aptamer Sequences
-
Target Identification & Aptamer Selection
-
Oligonucleotide Modification & Stabilization
-
Linker Design and Synthesis
-
Bioconjugation & Purification
-
In Vitro Validation & Efficacy Testing
Explore Our Expertise – Schedule Your Consultation Today!
Deliverables
Upon completion of the ApDCs Development Service, Creative Biolabs provides a comprehensive data package to ensure seamless transition to preclinical testing:
-
Final ApDC Product
-
Detailed Chemistry and Analytical Report
-
Biological Activity Report
-
Validated Starting Materials Report
Key Benefits
Creative Biolabs' ApDCs service offers distinct strategic advantages over generic conjugation services, ensuring your therapeutic moves faster and safer through the pipeline.
Exceptional Tumor Penetration
The small size of the ApDC ensures rapid, homogeneous distribution deep into the core of solid tumors, a critical advantage. This enhanced delivery leads to higher local drug concentrations and improved efficacy.
Reduced Off-Target Toxicity
Our Stimuli-Responsive Linker Library is engineered for maximum stability in circulation and rapid cleavage only inside the lysosomal environment of the target cell. This minimizes the risk of payload release in healthy tissue, greatly improving the therapeutic window.
High Purity and Reproducibility
Unlike the heterogeneous products often resulting from antibody conjugation, ApDCs are synthesized chemically. This allows for site-specific conjugation and a precise, predefined Drug-to-Aptamer Ratio (DAR), guaranteeing batch-to-batch consistency and simplifying regulatory submission.
Versatile Payload Options
Our platform is compatible with a wide array of cytotoxic drugs, including highly potent tubulin inhibitors and DNA-damaging agents. We also offer expertise in conjugating complex oligonucleotide payloads (siRNA, miRNA) for gene therapy combination strategies.
Tap into the Creative Biolabs Advantage – Obtain Your Quote Today!
Related Products
Frequently Asked Questions
Q: How does the stability of ApDCs compare to traditional ADCs in the bloodstream?
A: Aptamers, especially those modified with 2'-fluoro-pyrimidines or PEGylation, exhibit exceptional nuclease resistance. They are often more stable than antibodies in non-refrigerated conditions and, unlike ADCs, their stability is entirely chemically controlled. We specifically engineer our ApDCs to maintain stability in plasma for the required therapeutic duration, ensuring the payload is only released upon reaching the tumor cell.
Q: Can Creative Biolabs help identify new targets if my current antibody approach is failing?
A: Absolutely. ApDCs can be screened against targets that are challenging for antibodies, including non-protein targets and small molecules. We utilize sophisticated Cell-SELEX techniques, which can be performed on live cancer cell lines to select aptamers that recognize the target in its native, functional conformation, even if the precise molecular identity is unknown.
Q: I have a unique, highly potent drug payload. Can your platform handle its conjugation?
A: Yes. Our platform specializes in handling diverse payloads. We work with various conjugation chemistries to ensure that the drug is precisely linked to the aptamer. We will conduct preliminary feasibility studies to identify the optimal linking strategy that preserves the activity of your potent drug while ensuring the stability of the final conjugate.
Contact Us
Creative Biolabs' ApDCs Development Service is positioned at the forefront of the precision oncology revolution. By combining the specificity of aptamers with proprietary linker technology and efficient chemical synthesis, we offer a path to targeted therapeutics that are smaller, safer, and more scalable than previous generations of conjugates. We empower your team to accelerate the discovery of potent, tumor-penetrating cancer treatments. Contact our scientific team today to discuss your specific target, payload needs, and development goals.
Reference
-
Xiao, Yu, et al. "Aptamer-drug conjugates-loaded bacteria for pancreatic cancer synergistic therapy." Signal Transduction and Targeted Therapy 9.1 (2024): 272. Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.1038/s41392-024-01973-3.
For Research Use Only.
Related Sections:
